Press Releases
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
01/10/18Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’s existing commercial infrastructure CANTON, Mass., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has closed the transactions contemplated by its commercialization agreement (the “Agreement”) with Depomed, Inc. (“Depomed”) pu... 
Printer Friendly Version